Assessment of ABT-263 activity across a cancer cell line collection leads to a potent combination therapy for small-cell lung cancer
AC Faber, AF Farago, C Costa…�- Proceedings of the�…, 2015 - National Acad Sciences
BH3 mimetics such as ABT-263 induce apoptosis in a subset of cancer models. However,
these drugs have shown limited clinical efficacy as single agents in small-cell lung cancer�…
these drugs have shown limited clinical efficacy as single agents in small-cell lung cancer�…
mTOR Inhibition Specifically Sensitizes Colorectal Cancers with KRAS or BRAF Mutations to BCL-2/BCL-XL Inhibition by Suppressing MCL-1
AC Faber, EM Coffee, C Costa, A Dastur, H Ebi…�- Cancer discovery, 2014 - AACR
Colorectal cancers harboring KRAS or BRAF mutations are refractory to current targeted
therapies. Using data from a high-throughput drug screen, we have developed a novel�…
therapies. Using data from a high-throughput drug screen, we have developed a novel�…
Tracking the evolution of resistance to ALK tyrosine kinase inhibitors through longitudinal analysis of circulating tumor DNA
I Dagogo-Jack, AR Brannon, LA Ferris…�- JCO precision�…, 2018 - ascopubs.org
Purpose ALK (anaplastic lymphoma kinase) rearrangements predict for sensitivity to ALK
tyrosine kinase inhibitors (TKIs); however, responses to ALK TKIs are generally short lived�…
tyrosine kinase inhibitors (TKIs); however, responses to ALK TKIs are generally short lived�…
[HTML][HTML] The new-generation selective ROS1/NTRK inhibitor DS-6051b overcomes crizotinib resistant ROS1-G2032R mutation in preclinical models
R Katayama, BO Gong, N Togashi, M Miyamoto…�- Nature�…, 2019 - nature.com
ROS1 gene rearrangement was observed in around 1–2% of NSCLC patients and in
several other cancers such as cholangiocarcinoma, glioblastoma, or colorectal cancer�…
several other cancers such as cholangiocarcinoma, glioblastoma, or colorectal cancer�…
[HTML][HTML] Exploitation of the apoptosis-primed state of MYCN-amplified neuroblastoma to develop a potent and specific targeted therapy combination
J Ham, C Costa, R Sano, TL Lochmann, EM Sennott…�- Cancer cell, 2016 - cell.com
Fewer than half of children with high-risk neuroblastoma survive. Many of these tumors
harbor high-level amplification of MYCN, which correlates with poor disease outcome. Using�…
harbor high-level amplification of MYCN, which correlates with poor disease outcome. Using�…
[HTML][HTML] Programmed cell death ligand (PD-L1) expression in stage II and III lung adenocarcinomas and nodal metastases
H Uruga, E Bozkurtlar, TG Huynh, A Muzikansky…�- Journal of Thoracic�…, 2017 - Elsevier
Introduction Programmed death ligand 1 (PD-L1) expression determined by
immunohistochemistry (IHC) may serve as a predictive biomarker for anti–PD-1/PD-L1�…
immunohistochemistry (IHC) may serve as a predictive biomarker for anti–PD-1/PD-L1�…
[HTML][HTML] Cotargeting a MYC/eIF4A-survival axis improves the efficacy of KRAS inhibitors in lung cancer
F Nardi, N Perurena, AE Schade, ZH Li…�- The Journal of�…, 2023 - Am Soc Clin Investig
Despite the success of KRAS G12C inhibitors in non–small cell lung cancer (NSCLC), more
effective treatments are needed. One preclinical strategy has been to cotarget RAS and�…
effective treatments are needed. One preclinical strategy has been to cotarget RAS and�…
[HTML][HTML] Programmed cell death ligand 1 expression in resected lung adenocarcinomas: association with immune microenvironment
TG Huynh, V Morales-Oyarvide, MJ Campo…�- Journal of Thoracic�…, 2016 - Elsevier
Introduction Programmed cell death ligand 1 (PD-L1) expression on tumor cells can be
upregulated via activation of CD8+ cytotoxic T lymphocytes (CTLs) or the T helper cell (Th1)�…
upregulated via activation of CD8+ cytotoxic T lymphocytes (CTLs) or the T helper cell (Th1)�…
Exploiting MCL1 Dependency with Combination MEK + MCL1 Inhibitors Leads to Induction of Apoptosis and Tumor Regression in KRAS-Mutant Non–Small Cell�…
V Nangia, FM Siddiqui, S Caenepeel, D Timonina…�- Cancer discovery, 2018 - AACR
BH3 mimetic drugs, which inhibit prosurvival BCL2 family proteins, have limited single-agent
activity in solid tumor models. The potential of BH3 mimetics for these cancers may depend�…
activity in solid tumor models. The potential of BH3 mimetics for these cancers may depend�…
Failure to induce apoptosis via BCL-2 family proteins underlies lack of efficacy of combined MEK and PI3K inhibitors for KRAS-mutant lung cancers
Although several groups have demonstrated that concomitant use of MEK and
phosphoinositide 3-kinase (PI3K) inhibitors (MEKi/PI3Ki) can induce dramatic tumor�…
phosphoinositide 3-kinase (PI3K) inhibitors (MEKi/PI3Ki) can induce dramatic tumor�…